Navigation Links
Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today
Date:6/10/2013

cument and the Further Revised Offer Document), the federal securities laws of the United States may not be applicable.

Additional Information

Any response in relation to the Further Increased Offer (including any acceptance thereof) should be made only on the basis of the information contained in the Further Revised Offer Document, the Further Revised Acceptance Documents or any other document by which the Further Increased Offer is made.

Royalty Pharma reserves the right, with the consent of the Irish Takeover Panel, to elect to implement the acquisition of Elan by way of court-approved scheme of arrangement under Section 201 of the Companies Act 1963 of Ireland.

Responsibility Statements

The directors of Royalty Pharma accept responsibility for the information contained in this announcement, save that the only responsibility accepted by the directors of Royalty Pharma in respect of the information in this announcement relating to Elan, the Elan Group, the Board of Elan and the persons connected with them, which has been compiled from published sources, has been to ensure that such information has been correctly and fairly reproduced or presented (and no steps have been taken by the directors of Royalty Pharma to verify this information). To the best of the knowledge and belief of the directors of Royalty Pharma (having taken all reasonable care to ensure that such is the case), the information contained in this announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

The managing member of RP Management accepts responsibility for the information contained in this announcement, save that the only responsibility accepted by the managing member of RP Management in respect of the information in this announcement relating to Elan, the Elan Group, the Board of Elan and the per
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Royalty Pharma Acceptances Announcement
2. Royalty Pharma Responds To Elans Tysabri Valuation
3. Royalty Pharma Response To Elans "Categorical View On Value"
4. Royalty Pharma Recommends Elan Shareholders vote "NO" on each of the Elan Resolutions at the Elan extraordinary general meeting
5. Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
6. Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
7. Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share
8. Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash
9. Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
10. PDL BioPharma Completes Structured Financing and Royalty Transaction with Avinger
11. Royalty Rates for Pharmaceuticals & Biotechnology: Real-Deal Information for Hundreds of Transactions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015 Regen BioPharma, Inc. (OTCBB: RGBP) ... novel means of delivering its patented (US Patent ... tumors utilizing a clinically approved formulation as delivery ... with gene silencing therapeutics in which the gene ... whole body.  By utilizing a local delivery system, ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. , Aug. ... ; EURONEXT: SAN) and the life sciences team at ... care and outcomes for people with type 1 and ... treatments and devices with Google,s expertise in analytics, miniaturized ... explore how to improve diabetes care by developing new ...
(Date:8/31/2015)...  Qualcomm Incorporated (NASDAQ: QCOM ) today ... is collaborating with Davita Healthcare Partners and ... by Qualcomm Life,s 2net™ Device Connectivity Platform and ... informed interventions and better management of at-risk populations. ... Connect 2015 ecosystem conference taking place ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... 7, 2011  Tethys Bioscience has entered into an agreement ... employers measurably flatten the trajectory of their healthcare trends ... their employee populations. The agreement allows ACAP Health to ... as a component of its disease intervention programs. The ...
... 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ... and develops new uses for previously approved drugs and ... of the granting of a European patent with broad ... diketopiperazine which is the active ingredient of Ampion™.  The ...
Cached Medicine Technology:Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 2Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 3Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™ 2
(Date:8/31/2015)... FL (PRWEB) , ... August 31, 2015 , ... Southern ... companies – has teamed up with fellow South Walton property management company, ... eliminating extreme poverty in remote parts of the world. The two companies will collect ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... In an ... CDA Press, the expert guest author addressed the topic of treating back pain caused ... that, while steroids were shown to slightly improve physical function in patients suffering from ...
(Date:8/31/2015)... Madre, CA (PRWEB) , ... August 31, 2015 ... ... wound center management, recently opened registration for the company’s second Introduction to Hyperbaric ... be held October 15-18, 2015 aboard the Queen Mary Hotel in Long Beach, ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... program that is unique to the Lake Orion area. This program is one ... , WEmovestrong’s weight management program will incorporate group fitness and nutritional consultations ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... classes. , Starting September 1st they are offering pre and postnatal ... and "Healthy Body, Healthy Baby." , More information can be found at 248-601-6683. ...
Breaking Medicine News(10 mins):Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3Health News:Article on Steroid Use for Back Pain Highlights the Effectiveness of Surgery in Treating Disk Pain, says Dr. Seyed M. Rezaian 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4
... say , , MONDAY, Sept. 22 (HealthDay News) -- Poorer ... much longer to get to the hospital when a heart ... finds. , The finding suggests that patients without means may ... for time-sensitive care following a heart attack, the researchers noted. ...
... Remains Unchanged, BETHESDA, Md., Sept. 22 Hanger ... public offering of 2,500,000,shares of its common stock by ... a portion of the currently outstanding shares,issued to Ares ... all of,Hanger,s Series A Convertible Preferred Stock into common ...
... SACRAMENTO, Calif., Sept. 22 The California Office of,Traffic Safety ... riding in car safety seats. The 2008 rate of 94.4 ... a big jump of 6.7,percentage points over the 2007 rate ... time to kick off the national Child,Passenger Safety Week, September ...
... WASHINGTON, Sept. 22 An improved and more,accessible ... to help,people stay healthy, was launched today by ... Its new design and interactive health management ... use for consumers and,professionals., "Many Americans struggle ...
... computer model, it appears that comparing the benefits and ... women and their physicians choose appropriate screening strategies, according ... Archives of Internal Medicine , one of the ... commonly known as Pap smears, is credited with reducing ...
... Patients on statin medications 30% more likely to experience ... -- People who are taking cholesterol-lowering statin drugs -- ... more likely to suffer delirium after surgery, a Canadian ... neglected, experience for older people after any sort of ...
Cached Medicine News:Health News:Heart Attack Care Often Delayed for the Poor 2Health News:Heart Attack Care Often Delayed for the Poor 3Health News:Hanger Orthopedic Group, Inc. Announces Underwritten Public Offering by Shareholder 2Health News:Hanger Orthopedic Group, Inc. Announces Underwritten Public Offering by Shareholder 3Health News:Record Upsurge in State's Child Safety Seat Usage Marks Child Passenger Safety Week 2Health News:Improved healthfinder.gov Makes Health Information Quicker and Easier to Use 2Health News:Improved healthfinder.gov Makes Health Information Quicker and Easier to Use 3Health News:Model highlights benefits and risks of cervical cancer screening methods 2Health News:Cholesterol Drugs May Raise Post-Op Delirium Risk 2Health News:Cholesterol Drugs May Raise Post-Op Delirium Risk 3
Open blade design with aspiration capabilities for removing fluids from the operative site. 19 gauge wire....
Designed to provide open approaches of the keratome to the cornea for either the left or right eye. Lightweight wire design adds to the comfort of the instrument when in place....
Solid 14 mm free-swinging blades, suture posts, and stabilizing disk. Dull finish....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
Medicine Products: